NMN regulatory status in the UK: where it landed

NMN has one of the more confusing regulatory stories in the supplement world, partly because the United States, the European Union and the UK moved in different directions at different times. This post sets out where things landed for a UK reader. It is editorial commentary, not legal advice. We do not sell NMN.

The short version

In the UK, NMN is legal to sell as a food supplement. It sits under the Food Supplements (England) Regulations 2003 and the equivalent rules in the devolved nations. EFSA, the European Food Safety Authority, has issued a positive safety opinion on NMN. NMN is not yet formally authorised as a novel food in the European Union, and the overall position continues to evolve. That is the accurate summary, and the rest of this post explains how each piece came to be.

The United States back-and-forth

Much of the confusion traces to the United States. In late 2022 the FDA took the view that NMN could no longer be marketed as a dietary supplement, because it had become the subject of an investigational new drug application, and US rules can exclude an ingredient from supplement status once it is being studied as a drug. That decision was paused and then partially reversed amid industry pushback.

The relevance to UK readers is indirect but real: a lot of NMN marketing copy and a lot of online commentary is written from a US perspective, so UK shoppers encounter American regulatory drama that does not describe the UK position. The UK did not follow the FDA’s reclassification.

The EU novel-food process and EFSA’s opinion

In the European Union, NMN has been moving through the novel-food framework, which governs ingredients without a significant history of consumption before 1997. As part of that process, EFSA assessed the safety of NMN and issued a positive safety opinion. A positive EFSA safety opinion is a meaningful step, but it is not the same as full novel-food authorisation, which is a separate formal act. As of now, NMN is not yet formally authorised as an EU novel food, and that authorisation is the piece still outstanding.

It is worth being precise here, because marketing copy sometimes blurs a safety opinion into a full authorisation. They are different things. The honest statement is: positive safety opinion yes, formal novel-food authorisation not yet.

Where the UK actually sits

In the UK, NMN is treated as a food supplement and is legal to sell on that basis. The practical consequences for a shopper are twofold. First, NMN is widely available from UK retailers, as the NMN sub-hub describes. Second, because it is a food supplement and not a licensed medicine, a brand cannot make medicinal claims on the label. Wording such as “supports NAD+ levels” sits on the permitted side of FSA and CAP rules. Wording that says NMN treats, reverses or cures anything does not.

This is the same regulatory logic that applies to NR, nicotinamide riboside, covered in the nicotinamide riboside post, and it mirrors how the wider NAD+ category splits along route lines, set out in the NAD+ landscape page.

Why the status keeps moving

The reason this page needs occasional updating is that the EU novel-food process is ongoing, post-Brexit UK and EU rules can diverge over time, and brands respond to each shift by adjusting what they stock and how they label. None of this changes the day-to-day reality that NMN is currently legal to buy in the UK as a food supplement. It does mean the precise wording of its status is a moving target, which is why we keep the NMN sub-hub current rather than treating any one snapshot as final.

For the consumer-facing implications of all this, the NMN label-reading post covers the wording you will actually see on a product, and why food-supplement language is a feature of the regulation rather than a brand being cagey.